Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Actelion Ltd. (ATLN), the Swiss drugmaker that gets almost 90 percent of sales from a treatment for a rare lung disease, raised its full-year profit forecast as second-quarter sales beat estimates and it cut spending. Core earnings will increase by a double-digit percentage in local currencies, compared with a previous forecast for them to be unchanged this year, the Allschwil-based company said in a statement today. The brighter outlook may renew takeover speculation, said Andrew Weiss, an analyst at Bank Vontobel AG in Zurich.
Help employers find you! Check out all the jobs and post your resume.
